Mounjaro vs. Ozempic — Full Comparison 2026

Two medications have dominated conversations about weight management and metabolic health in recent years: Mounjaro (tirzepatide) and Ozempic (semaglutide). Both belong to the broader family of incretin-based therapies, and both have transformed how clinicians approach obesity and type 2 diabetes. But they are not the same drug, and the differences between them matter — sometimes significantly — depending on your personal health goals, medical history, and budget.

This comprehensive guide breaks down everything you need to know about Mounjaro vs. Ozempic in 2026: how each works, what the clinical trials actually show, how their side effect profiles compare, and how to think about which one might be right for you. As always, your prescribing physician makes the final call — but an informed patient is always better positioned to have that conversation.

The Science: How Each Drug Works

Ozempic (Semaglutide) — GLP-1 Receptor Agonist

Ozempic contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a hormone naturally produced in the gut after eating. It signals the pancreas to release insulin, tells the brain you're full, slows gastric emptying, and suppresses glucagon (a hormone that raises blood sugar). By mimicking GLP-1 with a longer-acting synthetic version, semaglutide keeps these effects active for a full week after a single subcutaneous injection.

Ozempic was originally FDA-approved in 2017 for type 2 diabetes. Its sibling drug, Wegovy, uses the same molecule (semaglutide 2.4 mg) at a higher dose and is FDA-approved specifically for chronic weight management.

Mounjaro (Tirzepatide) — Dual GIP + GLP-1 Agonist

Mounjaro contains tirzepatide, which adds a second mechanism: it activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP is another incretin hormone released after eating that enhances insulin secretion, promotes fat storage in adipose tissue at lower doses, and — crucially — when combined with GLP-1 signaling, appears to amplify appetite suppression and energy expenditure in ways that GLP-1 alone does not fully achieve.

Mounjaro was FDA-approved in 2022 for type 2 diabetes. Its weight-management counterpart, Zepbound (tirzepatide 5–15 mg), received FDA approval for obesity in late 2023 and has rapidly gained traction as potentially the most powerful weight-loss medication ever approved.

Weight Loss Results: What the Trials Show

Clinical trial data is the most objective way to compare these two medications. Here's what the landmark studies found:

Ozempic / Semaglutide Trials

• SUSTAIN-6 (2016): In patients with type 2 diabetes, semaglutide 1 mg reduced body weight by approximately 4.5 kg over 104 weeks vs. 0.9 kg with placebo.
• STEP 1 Trial (2021): Using the higher 2.4 mg dose (Wegovy formulation), patients without diabetes lost an average of 14.9% of body weight over 68 weeks vs. 2.4% for placebo — a difference of roughly 12.5 percentage points.
• Approximately 1 in 3 participants in STEP 1 lost ≥20% of their body weight.

Mounjaro / Tirzepatide Trials

• SURPASS-2 (2021): Tirzepatide 15 mg reduced A1C by 2.46 percentage points and body weight by 12.4 kg in patients with type 2 diabetes, compared to 9.4 kg for semaglutide 1 mg — a statistically significant difference.
• SURMOUNT-1 (2022): In people with obesity (no diabetes), tirzepatide 15 mg produced an average weight loss of 22.5% over 72 weeks vs. 2.4% for placebo — by far the largest weight loss ever recorded in a phase 3 trial for a medication.
• More than half (57%) of participants on tirzepatide 15 mg lost ≥20% of body weight.

Head-to-Head Comparison Table

Feature	Ozempic / Wegovy (Semaglutide)	Mounjaro / Zepbound (Tirzepatide)
Mechanism	GLP-1 receptor agonist	GLP-1 + GIP dual agonist
Avg. weight loss (obesity trials)	~14.9% (STEP 1, 68 wks)	~22.5% (SURMOUNT-1, 72 wks)
% achieving ≥20% weight loss	~32%	~57%
A1C reduction (T2D trials)	~1.5–1.8% (1 mg dose)	~2.0–2.5% (15 mg dose)
Dosing frequency	Once weekly injection	Once weekly injection
Available doses	0.25, 0.5, 1, 2 mg (Ozempic); 2.4 mg (Wegovy)	2.5, 5, 7.5, 10, 12.5, 15 mg
FDA-approved for weight loss?	Wegovy (semaglutide 2.4 mg): Yes	Zepbound (tirzepatide): Yes
Cardiovascular outcome data	SELECT trial: 20% reduction in MACE	SURMOUNT-MMO ongoing (results expected 2026)
List price (monthly, approx.)	~$900–$1,000 (brand)	~$1,000–$1,100 (brand)
Compounded access via telehealth	Yes (semaglutide)	Yes (tirzepatide)

A1C and Blood Sugar Control

For patients with type 2 diabetes, both medications are highly effective at reducing A1C. Tirzepatide has generally demonstrated superior A1C reductions across the SURPASS trial program, particularly at higher doses. In SURPASS-2, tirzepatide 15 mg produced an A1C reduction of 2.46% vs. 1.86% for semaglutide 1 mg — a clinically meaningful difference that may matter for patients with poorly controlled diabetes.

For patients primarily seeking weight management without diabetes, the distinction in glycemic control matters less. Both drugs improve insulin sensitivity and fasting glucose even in non-diabetic patients with obesity, which may reduce future diabetes risk.

Side Effect Profiles

Both medications share a similar side effect profile, largely because of their overlapping GLP-1 mechanism. The most common side effects are gastrointestinal:

• Nausea (most common, especially during dose escalation)
• Vomiting
• Diarrhea
• Constipation
• Abdominal discomfort or bloating

These effects are typically most pronounced during the first 4–8 weeks and tend to diminish as the body adjusts. Slow dose titration — starting at a low dose and escalating gradually — is the key strategy for minimizing GI side effects.

Rare but serious risks associated with both drugs include:

• Pancreatitis
• Gallbladder disease (cholecystitis, gallstones — possibly related to rapid weight loss)
• Thyroid C-cell tumors (seen in rodent studies; contraindicated in patients with personal or family history of medullary thyroid cancer or MEN2)
• Diabetic retinopathy complications (reported in some semaglutide trials in diabetic patients)

In head-to-head trial comparisons (SURPASS-2), GI side effects were reported at broadly similar rates between semaglutide and tirzepatide, though the direct comparison used semaglutide 1 mg rather than the higher 2.4 mg weight-loss dose.

Who Should Choose Mounjaro (Tirzepatide)?

Tirzepatide may be the preferred choice if:

• You have significant weight to lose and want the most aggressive option currently available
• You have type 2 diabetes with poorly controlled A1C and need robust glycemic reduction
• You have already tried semaglutide and experienced inadequate weight loss
• You are comfortable with higher upfront costs in exchange for stronger results

Who Should Choose Ozempic / Wegovy (Semaglutide)?

Semaglutide may be the preferred choice if:

• You have documented cardiovascular disease and want the medication with the most established cardiac outcome data (SELECT trial)
• You have had a positive prior response to semaglutide and don't need to switch
• Formulary coverage or cost is a determining factor (insurance coverage varies; semaglutide has been on the market longer)
• You are sensitive to GI side effects and want to start with the lower-dose escalation ladder

Cost and Access in 2026

Brand-name pricing for both medications is high — typically $900–$1,100 per month without insurance. Coverage has expanded significantly, particularly for branded products when prescribed for obesity (Wegovy, Zepbound) rather than diabetes (Ozempic, Mounjaro), but many patients still pay out of pocket.

Compounded versions of both semaglutide and tirzepatide have been available through telehealth platforms during periods of FDA-documented shortage. These compounded formulations can meaningfully reduce costs and improve access. Patients interested in compounded GLP-1s should work with a licensed telehealth provider to understand the current regulatory landscape, which continues to evolve.

Long-Term Use and Discontinuation

One of the most important clinical realities about both semaglutide and tirzepatide is that their effects are not permanent. Multiple withdrawal studies — most notably STEP 4 for semaglutide and SURMOUNT-4 for tirzepatide — have demonstrated that patients who discontinue treatment typically regain most of their lost weight within 12 months, along with the associated cardiometabolic risk factors (blood pressure, blood sugar, lipids) that had improved.

This positions both medications as long-term chronic disease treatments rather than short courses of therapy. The implications for patients include:

• Planning for ongoing treatment rather than a defined "stop date"
• Prioritizing lifestyle changes — dietary patterns and physical activity — that can help sustain results if medication is ever discontinued
• Understanding that needing to continue medication long-term is not a personal failure but a reflection of the underlying biology of obesity as a chronic condition

Some patients are able to reduce to a lower maintenance dose after achieving their target weight, which can reduce both cost and side effect burden. Your prescribing physician can help evaluate whether dose reduction is appropriate as you progress.

Monitoring and Lab Work

Both medications require periodic monitoring. Before starting either drug, most clinicians will obtain:

• Fasting blood glucose or HbA1c (to establish baseline metabolic status)
• Complete metabolic panel (kidney and liver function)
• Thyroid function (TSH), given the theoretical concern about thyroid C-cell effects
• Lipid panel (to document baseline cardiovascular risk)

Follow-up labs are typically performed at 3 and 6 months, then annually in stable patients. In patients with diabetes, more frequent glucose monitoring may be required, particularly as blood sugar improves and existing diabetes medications may need to be adjusted to avoid hypoglycemia.

Combination Therapy and Emerging Options

As of 2026, several next-generation obesity medications are in late-stage clinical development, including triple agonists targeting GLP-1, GIP, and glucagon receptors simultaneously (such as retatrutide), oral semaglutide formulations, and once-monthly injectable options. These emerging therapies may ultimately offer even greater weight loss than tirzepatide, but none have yet reached the market at scale.

For patients who have experienced an inadequate response to one GLP-1 based therapy, switching to the alternative drug class rather than abandoning pharmacotherapy altogether is a common and evidence-supported strategy. A patient who lost only 5–7% body weight on semaglutide may find that tirzepatide's additional GIP mechanism provides a more meaningful response — and vice versa, though anecdotally the switch from tirzepatide back to semaglutide is less common.

Combination of GLP-1 therapy with other evidence-based interventions — a structured dietary program, behavioral coaching, and regular physical activity — consistently outperforms medication alone. These are complementary tools, not competing ones. Your Truventa physician can help coordinate a comprehensive approach tailored to your specific health history and goals.

Accessing Both Medications Through Truventa Medical

Truventa Medical offers access to both semaglutide and tirzepatide-based weight loss programs via telehealth, with licensed physicians available in all 50 states. Our clinical team will review your health history, metabolic goals, and medication history to help determine which approach is most appropriate for you — entirely online, with no in-person office visit required.

Our programs include ongoing clinical monitoring, dose titration support, and access to lifestyle resources to maximize your outcomes. Results may vary based on individual factors including adherence, diet, activity level, and baseline metabolic health.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Results may vary. Consult your doctor before starting any new treatment.